Our vision is for Cannulight devices to become the indispensable aids to every peripheral intra venous catheterization (PIVC), and to improve patient and clinician outcomes and experiences in all situations.
Born from practice. Built for confidence.
Cannulight was born from the frustrations of Dr. James Stone, who found that establishing IV access brought a stressful and unpredictable aspect to his surgeries. Too many patients went home untreated after multiple failed attempts, leaving both patient and clinician discouraged. Determined to fix this, James created a simple, elegant solution: a pressure-sensing device that lights up the moment you’re in the vein and switches off if you’re not. What started as a personal need has grown into a refined innovation that gives clinicians confidence and patients a better experience.
Our Story
Cannulight Technology Limited is a New Zealand based medical device company (with USA, UK, and Australian subsidiaries), founded by the inventor of the Cannulight device, Dr James Stone.
The device was created to help clinicians with the difficult task of Peripheral IntraVenous Catheter (PIVC) insertions, which can have a failure rate of between 35-75%1. PIVC insertion failure can cause profound health problems to patients, significant stress to clinicians, and negative financial consequences to healthcare organizations.
About Cannulight Technology Limited.
Potential of Cannulight
Every year, over 1.4 billion IV lines 2 are placed worldwide, and with a 35 – 75%1 failure rate, nearly every patient will feel the impact of a missed stick. Cannulight addresses this global problem with a novel, simple device that confirms vein entry in real time, offering huge potential across hospitals, military, and developing healthcare systems. With a total addressable market of $24B and strong clinician feedback, including nearly half saying they’d use it on every patient, Cannulight stands apart as a unique innovation with the power to transform IV access at scale.
1Safe patient care when using vascular access devicesBritish Journal of Nursing January 2013 22(2):S14, S16, S18 passim DOI:10.12968/bjon.2013.22.Sup1.S14
2Alexandrou E et al. International prevalence of the use of peripheral intravenous catheters. J. Hosp. Med 10, 530–533 (2015).
Cannulight has moved quickly from idea to impact, achieving key milestones that validate both our innovation and our market opportunity. With U.S. Military testing undertaken, we are now at manufacturing verification stage and preparing for 510(k) submission. Alongside military traction and patent filings, we are advancing new product versions, including infrared and arterial applications, while building momentum toward global hospital adoption.
LSI interview of James sharing these Milestones
Company Milestones
The team
Dr James Stone
Founder & CEO
Dental surgeon and innovator who created Cannulight after seeing the urgent need for a better way to place IV lines.
Val Theisz
Regulatory Affairs Advisor
Internationally recognised regulatory affairs expert with 25+ years’ experience in high-risk devices.
Mike Munley
Chief Operating Officer
Global healthcare executive with senior leadership roles across MedTech, pharma, and OTC sectors.
Dr Dennis Shay
Regulatory & Quality Advisor
Global leader in medical device regulatory and quality systems, with FDA and EU expertise.
Lynley Daley
Quality Manager
Experienced quality and compliance manager across pharmaceuticals, medical devices, and healthcare manufacturing.
Wendy Kerr
Chief Customer Officer
Strategic leader with global experience at Apple, FT.com, and Pearson.
Our Partners
Cannulight is currently available for purchase and use only in New Zealand. It has not yet been cleared or approved by the US FDA or other international regulatory authorities.
The information on this website is intended for New Zealand audiences only.